12 assets in Inborn Error Of Immunity

Therapeutic assets addressing Inborn Error Of Immunity, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Busulfanum Inborn Error Of Immunity	medac GmbH	P2	B (57)
Fludarabine Inborn Error Of Immunity	Paul Szabolcs	P2	B (57)
Alemtuzumab Inborn Error Of Immunity	Paul Szabolcs	P2	CCC (53)
Cyclophosphamide Inborn Error Of Immunity	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	P2	CCC (53)
Hydroxyurea Inborn Error Of Immunity	Paul Szabolcs	P2	CCC (53)
Melphalan Inborn Error Of Immunity	Paul Szabolcs	P2	CCC (53)
Tacrolimus Inborn Error Of Immunity	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	P2	CCC (53)
Thiotepa Inborn Error Of Immunity	Paul Szabolcs	P2	CCC (53)
Rimiducid Inborn Error Of Immunity	Bellicum Pharmaceuticals	P1/2	CCC (50)
Bpx-501 T Cells Inborn Error Of Immunity	Bellicum Pharmaceuticals	P1/2	CC (47)
Albuterol Inborn Error Of Immunity	Rambam Health Care Campus	N/A	D (30)